The epidemiology and clinical implications of genetic variation in prostate cancer (Q38203985)

31 August 2017

title

The epidemiology and clinical implications of genetic variation in prostate cancer (English)

1 reference

31 August 2017

1 reference

1 reference

1 reference

Brian T Helfand

1

1 reference

31 August 2017

William J Catalona

series ordinal

2

1 reference

31 August 2017

publication date

28 February 2014

1 reference

Urologic Clinics of North America

31 August 2017

published in

1 reference

31 August 2017

volume

41

1 reference

31 August 2017

issue

2

1 reference

31 August 2017

page(s)

277-297

1 reference

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

7 January 2021

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Improved stage and grade-specific progression-free survival rates after radical prostatectomy in the PSA era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Prostate-specific antigen and detection of prostate cancer: What have we learned and what should we recommend for screening?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Prostate-specific antigen screening: pro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Quality of life and satisfaction with outcome among prostate-cancer survivors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Radical prostatectomy versus observation for localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Mendelian inheritance of familial prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Genetic predisposition to prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Unravelling the genetics of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Identification of a novel NBN truncating mutation in a family with hereditary prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Inherited susceptibility for aggressive prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

National Cancer Institute Prostate Cancer Genetics Workshop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

The role of genetic markers in the management of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

The complex genetic epidemiology of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Cancer risks in BRCA2 mutation carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

The role of BRCA1 and BRCA2 in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Cellular functions of the BRCA tumour-suppressor proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Hallmarks of 'BRCAness' in sporadic cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Prostate Cancer Progression and Survival in BRCA2 Mutation Carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Decreased Prostate Cancer-Specific Survival of Men withBRCA2 Mutations from Multiple Breast Cancer Families

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Rapid progression of prostate cancer in men with a BRCA2 mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Germline BRCA mutations denote a clinicopathologic subset of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Elevated risk of prostate cancer among men with Lynch syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Hereditary prostate cancer as a feature of Lynch syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Frequency of extracolonic tumors in Brazilian families with Lynch syndrome: analysis of a hereditary colorectal cancer institutional registry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Variation is the spice of life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Molecular genetic studies of complex phenotypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Chromosomal basis of adenocarcinoma of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Review of allelic loss and gain in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

A common variant associated with prostate cancer in European and African populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Multiple loci on 8q24 associated with prostate cancer susceptibility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Confirmation study of prostate cancer risk variants at 8q24 in African Americans identifies a novel risk locus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Myc-driven murine prostate cancer shares molecular features with human prostate tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Genome-wide association study of prostate cancer identifies a second risk locus at 8q24

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Functional enhancers at the gene-poor 8q24 cancer-linked locus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Evaluation of the 8q24 prostate cancer risk locus and MYC expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

A functional variant at a prostate cancer predisposition locus at 8q24 is associated with PVT1 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Inherited susceptibility to common cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Established prostate cancer susceptibility variants are not associated with disease outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Cumulative association of five genetic variants with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Combined Genome-Wide Scan for Prostate Cancer Susceptibility Genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Germline mutations in HOXB13 and prostate-cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Association between germline HOXB13 G84E mutation and risk of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

A novel germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Estimation of absolute risk for prostate cancer using genetic markers and family history

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Prostate cancer risk alleles significantly improve disease detection and are associated with aggressive features in patients with a “normal” prostate specific antigen and digital rectal examination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Replication and cumulative effects of GWAS-identified genetic variations for prostate cancer in Asians: a case-control study in the ChinaPCa consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Common variants at 8q24 are associated with prostate cancer risk in Taiwanese men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Number of prostate cancer risk alleles may identify possibly 'insignificant' disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

An expanded risk prediction model for lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Prospective breast cancer risk prediction model for women undergoing screening mammography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Genetic correction of PSA values using sequence variants associated with PSA levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Prostate cancer disparities in Black men of African descent: a comparative literature review of prostate cancer burden among Black men in the United States, Caribbean, United Kingdom, and West Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Epidemiology, pathology, and genetics of prostate cancer among African Americans compared with other ethnicities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

A systematic review of replication studies of prostate cancer susceptibility genetic variants in high-risk men originally identified from genome-wide association studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Chromosome 8q24 variants are associated with prostate cancer risk in a high risk population of African ancestry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Genetic polymorphism and prostate cancer aggressiveness: a case-only study of 1,536 GWAS and candidate SNPs in African-Americans and European-Americans.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Characterizing genetic risk at known prostate cancer susceptibility loci in African Americans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

GWAS SNP Replication among African American and European American men in the North Carolina-Louisiana prostate cancer project (PCaP)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Replication of prostate cancer risk loci on 8q24, 11q13, 17q12, 19q33, and Xp11 in African Americans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Prostate cancer risk associated loci in African Americans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Validation of genome-wide prostate cancer associations in men of African descent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Prostate-specific antigen testing and prostate cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Heritability of cardiovascular and personality traits in 6,148 Sardinians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Germline Sequence Variants and Prostate-Specific Antigen Interpretation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Identification of new genetic risk factors for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Prostate cancer susceptibility variants confer increased risk of disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Association of prostate-specific antigen promoter genotype with clinical and histopathologic features of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Tagging SNPs in the kallikrein genes 3 and 2 on 19q13 and their associations with prostate cancer in men of European origin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Common variation in KLKB1 and essential hypertension risk: tagging-SNP haplotype analysis in a case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Fine mapping the KLK3 locus on chromosome 19q13.33 associated with prostate cancer susceptibility and PSA levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Prostate cancer: improving PSA testing by adjusting for genetic background

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Genetic polymorphisms in inflammation pathway genes and prostate cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Replication of the 10q11 and Xp11 prostate cancer risk variants: results from a Utah pedigree-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Genome-wide association study of prostate cancer mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Common variants in 8q24 are associated with risk for prostate cancer and tumor aggressiveness in men of European ancestry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Inherited genetic variant predisposes to aggressive but not indolent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Prostate cancer predisposition loci and risk of metastatic disease and prostate cancer recurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Association of prostate cancer risk variants with clinicopathologic characteristics of the disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

The common variant rs1447295 on chromosome 8q24 and prostate cancer risk: results from an Australian population-based case-control study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Sequence variants at 22q13 are associated with prostate cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Genetic susceptibility to aggressive prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Prostate cancer risk alleles are associated with prostate cancer volume and prostate size.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Genomewide scan for prostate cancer-aggressiveness loci.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Prostate cancer aggressiveness locus on chromosome 7q32-q33 identified by linkage and allelic imbalance studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Fine‐mapping of prostate cancer aggressiveness loci on chromosome 7q22–35

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Family-based association analysis of 42 hereditary prostate cancer families identifies the Apolipoprotein L3 region on chromosome 22q12 as a risk locus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Genomic search for prostate cancer predisposition loci in Utah pedigrees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Macrophage Inhibitory Cytokine-1 H6D Polymorphism, Prostate Cancer Risk, and Survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Association of vitamin D receptor FokI polymorphism with prostate cancer risk, clinicopathological features and recurrence of prostate specific antigen after radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

AMACR polymorphisms, dietary intake of red meat and dairy and prostate cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Association of caveolin-1 and -2 genetic variants and post-treatment serum caveolin-1 with prostate cancer risk and outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Association of CASP8 D302H polymorphism with reduced risk of aggressive prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels and prostate cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Paraoxonase 1 (PON1) polymorphisms and prostate cancer in the CPS-II Nutrition Cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Podocalyxin variants and risk of prostate cancer and tumor aggressiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Genetic polymorphisms in the human tissue kallikrein (KLK) locus and their implication in various malignant and non-malignant diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Multiple newly identified loci associated with prostate cancer susceptibility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers--results from BPC3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

HOXB13 mutations in a population-based, case-control study of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Genetic architecture of cancer and other complex diseases: lessons learned and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

The genomic complexity of primary human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Exome sequencing of prostate cancer supports the hypothesis of independent tumour origins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Potential biomarkers for differentiation of benign prostatic hyperplasia and prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

[Use of [-2] pro PSA and phi index for early detection of prostate cancer: a prospective of 452 patients]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Cost-effectiveness of Prostate Health Index for prostate cancer detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROME

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Integrative genomic profiling of human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Somatic alterations contributing to metastasis of a castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Genetic markers associated with early cancer-specific mortality following prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Genetics and genomics of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Copy number alterations in prostate tumors and disease aggressiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Recurrent gene fusions in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Activating BRAF gene mutations are uncommon in hormone refractory prostate cancer in Caucasian patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

ETS gene fusions in prostate cancer: from discovery to daily clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

The mutational landscape of lethal castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Identification of seven new prostate cancer susceptibility loci through a genome-wide association study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Two variants on chromosome 17 confer prostate cancer risk and the one in TCF2 protects against type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Genome-wide association study identifies new prostate cancer susceptibility loci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Multiple loci identified in a genome-wide association study of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Progensa PCA3 test for prostate cancer detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Accurate prediction of repeat prostate biopsy outcomes by a mitochondrial DNA deletion assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

Impact of a genomic classifier of metastatic risk on postoperative treatment recommendations for prostate cancer patients: a report from the DECIDE study group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2014.01.001

10.1016/J.UCL.2014.01.001

7 January 2021

Identifiers

DOI

1 reference

31 August 2017

1 reference